Identify clinically effective combinations
Validate patient selection biomarkers
Assess novel target pathways
Returning for the third year, ICI Boston 2017 is the only conference that focuses exclusively on delivering maximum clinical benefit through immune checkpoint monotherapy and combinations, from pathway validation to clinical success.
Gain in-depth insights from Merck, BMS, Genentech, MedImmune, Novartis and EMD Serono and transform the success of your immuno-oncology approach.
Rather than replicating broad immuno-oncology conferences, the narrow focus of this immune checkpoint meeting enables an unprecedented depth of content. Deliver robust and durable responses through rational combinations, examine next generation biomarker approaches to successfully stratify patients for clinical success and learn about checkpoint pathways beyond T cells to maximize the holistic anti-tumor response.
Hear What Previous ICI Boston Attendees Have To Say:
‘Great Meeting, very informative, great to see what other companies are working on in the field of cancer immunotherapy.’ Genentech
‘I took away a lot of information and really enjoyed the conference…..I learned a lot and enjoyed it.’ Merck
‘Great meeting for an over-view on the iONC landscape. I enjoyed the versatility of the talks and the opportunity to network with peers.’ EMD Serono
|Past Attendees Included: